Related Experiment Video
Updated: Sep 6, 2025

Ileectomy-induced Bile Overaccumulation in Mouse Intestine
Published on: August 21, 2017
Effects of Intestinal FXR-Related Molecules on Intestinal Mucosal Barriers in Biliary Tract Obstruction
Meng Yan1,2, Li Hou1, Yaoyao Cai1
1Department of Pediatric Surgery, Children's Hospital of Nanjing Medical University, Nanjing, China.
Abstract:
Background: The farnesoid X receptor (FXR) is a key factor regulating hepatic bile acid synthesis and enterohepatic circulation. Repression of bile acid synthesis by the FXR is a potential strategy for treating cholestatic liver disease. However, the role of intestinal FXR on the intestinal barrier and intestinal microbiota needs further investigation. Materials: Intestinal tissues were collected from patients with biliary atresia or without hepatobiliary disease. Then, intestinal mRNA levels of FXR-related molecules were determined. To investigate the effect of FXR activation, bile-duct-ligation rats were treated with obeticholic acid [OCA (5 mg/kg/day)] or vehicle (0.5% methyl cellulose) per oral gavage for 14 days. The mRNA levels of intestinal FXR, SHP, TNF-α, FGF15 and bile acid transporter levels were determined. In addition, the intestinal permeability, morphologic changes, and composition of the intestinal microbiota were evaluated. Gut Microbiome was determined by 16S rDNA MiSeq sequencing, and functional profiling of microbial communities was predicted with BugBase and PICRUSt2. Finally, the role of OCA in injured intestinal epithelial cell apoptosis and proliferation was examined by pretreatment with lipopolysaccharide (LPS) in Caco-2 cells. Results: The downstream of the FXR in ileum tissues was inhibited in biliary obstruction. Activation of the FXR signaling pathway by OCA significantly reduced liver fibrosis and intestinal inflammation, improved intestinal microbiota, and protected intestinal mucosa in BDL rats. OCA also altered the functional capacities of ileum microbiota in BDL rats. Significant differences existed between the controls and BDL rats, which were attenuated by OCA in the alpha diversity analysis. Principal coordinates analysis showed that microbial communities in BDL rats clustered separately from controls, and OCA treatment attenuated the distinction. Bugbase and PICRUSt2 analysis showed that OCA changed the composition and structure of the intestinal microbiota and improved the metabolic function of the intestinal microbiota by increasing the relative abundance of beneficial bacteria and reducing the relative abundance of harmful bacteria. Moreover, OCA reduced the apoptosis induced by LPS in Caco-2 cells. Conclusion: The FXR agonist, OCA, activates the intestinal FXR signaling pathway and improves the composition and structure of the intestinal microbiota and intestinal barrier in BDL rats.
Insights
The farnesoid X receptor (FXR) agonist obeticholic acid (OCA) improves intestinal barrier function and microbiota in bile duct-ligated rats. OCA treatment reduces liver fibrosis and inflammation, promoting gut health by modulating bacterial composition and function.
Area of Science:
- Gastroenterology and Hepatology
- Microbiology and Immunology
- Pharmacology
Background:
- Farnesoid X receptor (FXR) is crucial for bile acid homeostasis and a therapeutic target for cholestatic liver diseases.
- The impact of intestinal FXR on the intestinal barrier and microbiota remains incompletely understood.
- Bile duct ligation (BDL) in rats serves as a model to study cholestatic liver injury and its effects on the gut.
Purpose of the Study:
- To investigate the role of intestinal FXR activation in response to bile duct ligation.
- To evaluate the effects of the FXR agonist obeticholic acid (OCA) on intestinal barrier function, inflammation, and microbiota.
- To assess OCA's impact on liver fibrosis and intestinal epithelial cell apoptosis in a rat model of cholestasis.
Main Methods:
- Intestinal tissues from patients and bile duct-ligated (BDL) rats treated with OCA or vehicle were analyzed for FXR-related gene expression.
- Intestinal permeability, morphology, and microbiota composition (16S rDNA sequencing) were assessed in BDL rats.
- Functional microbial profiling (BugBase, PICRUSt2) and Caco-2 cell apoptosis assays were performed.
Main Results:
- OCA treatment significantly reduced liver fibrosis and intestinal inflammation in BDL rats.
- OCA improved intestinal barrier integrity and modulated the gut microbiota, increasing beneficial bacteria and enhancing metabolic function.
- OCA decreased LPS-induced apoptosis in Caco-2 cells, suggesting a protective effect on intestinal epithelial cells.
Conclusions:
- Intestinal FXR activation by OCA improves gut barrier function and modulates the intestinal microbiota in cholestatic liver injury.
- OCA demonstrates therapeutic potential by mitigating liver fibrosis, reducing inflammation, and protecting the intestinal mucosa.
- FXR agonists represent a promising strategy for managing complications associated with cholestatic liver diseases.
More Related Videos
Related Concept Videos
Chronic Bowel Disorders: Introduction
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Hepatic Drug Excretion: Influencing Factors
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Irritable Bowel Syndrome I: Introduction
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

